Wang W, Sheng X, Shu Z, Li D, Pan J, Ye X, Chang P, Li X, Wang Y
I previously compared Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) (NONOF) in August 2025, discussing how the prior compounding/regulatory headwinds had triggered their painful corrections, worsened by Analysts Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours
Odczynnik dual-agonista GLP-1/GIP RUO nie jest tym lekiem nie posiada jego dokumentacji, jakoci farmaceutycznej ani autoryzacji do podania u ludzi
I think there is considerable potential for this drug (and class) as a treatment for obstructive sleep apnea
Aside from semaglutide and tirzepatide, other notable GLP-1 agonists are dulaglutide, liraglutide, and exenatide
Natural GLP-1 supplements are generally well-tolerated